BeOne Medicines (NASDAQ:ONC) is a global biopharmaceutical company pioneering a new era of cancer care by developing innovative, targeted therapies designed to be more effective, more accessible, and more affordable for patients worldwide. Formerly known as BeiGene, the company underwent a significant corporate transformation in early 2025—rebranding as BeOne Medicines, relocating its corporate headquarters to Basel, Switzerland, and adopting a new NASDAQ ticker symbol: ONC. These strategic changes reflect the company’s growing scale, global ambitions, and intensified focus on delivering meaningful solutions across both hematologic malignancies and solid tumors.
Founded in 2010 by biotech visionary John V. Oyler and renowned scientist Xiaodong Wang, the company was built on a mission to radically improve access to high-quality cancer therapeutics. What began as an ambitious oncology startup has since evolved into a multinational R&D and commercial juggernaut, now employing over 11,000 professionals across six continents, including scientists, clinicians, and commercial specialists dedicated to transforming the future of cancer treatment.
BeOne’s product and research pipeline are rooted in biology-driven innovation, leveraging deep understanding of cancer pathways, resistance mechanisms, and patient-specific molecular profiles. The company’s most well-known therapy, Brukinsa® (zanubrutinib)—a next-generation BTK inhibitor—has achieved regulatory approvals in dozens of countries and surpassed $1 billion in annual global revenue, making it the first China-originated cancer drug to reach blockbuster status on a global scale. This success has positioned BeOne as one of the most accomplished oncology-focused biotechs in history, and as a top-tier competitor in the global BTK inhibitor market.
Beyond Brukinsa, BeOne’s pipeline spans hematology, breast cancer, lung cancer, and gynecologic cancers, with programs targeting critical unmet needs through novel mechanisms such as antibody-drug conjugates (ADCs), CDK inhibitors, BCL2 inhibitors, multispecific antibodies, and targeted protein degraders. Its integrated development model allows it to rapidly bring molecules from discovery to global clinical trials, with facilities and collaborations across North America, Europe, and Asia. Notably, its expanding research hubs in Hopewell, New Jersey, and Beijing, along with its commercial reach in the U.S., China, and the EU, allow the company to operate with exceptional agility and scale.
BeOne Medicines is not just focused on innovation, but on access. The company’s mission is to close the global cancer treatment gap by offering advanced therapies to more patients in more regions—especially underserved populations. Its commercial model emphasizes both affordability and availability, supported by its unique multinational infrastructure and collaborative regulatory strategy.
With its bold new identity, robust pipeline, strong financial momentum, and a purpose-driven mission, BeOne Medicines is emerging as one of the most important oncology companies of the modern biotech era. As cancer remains one of the world’s leading causes of death, BeOne is answering the call with a powerful combination of scientific rigor, patient focus, and global execution.
Promising ASCO 2025 Data Signals a Breakthrough in Breast Cancer R&D
At the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, BeOne Medicines unveiled two first-in-human Phase 1a studies that highlight the depth and differentiation of its emerging breast cancer pipeline. These clinical readouts centered on BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC), and BG-68501, a potent CDK2 inhibitor aimed at overcoming resistance to current CDK4/6 inhibitors in HR+/HER2- breast cancer.
The presentation of these data represents a major milestone in BeOne’s solid tumor program. According to Dr. Mark Lanasa, Chief Medical Officer for Solid Tumors, this data is “just the beginning of a pipeline built on targeted, biology-driven innovation.” With the debut of the BeOne identity and branding now complete, the company is using these studies to showcase its capacity to drive both scientific excellence and global relevance in cancer research.
BG-C9074: A Next-Generation Antibody-Drug Conjugate for Breast and Gynecologic Cancers
BG-C9074 is an investigational ADC that targets B7-H4, a protein broadly expressed in breast and gynecologic tumors. The Phase 1a dose escalation study enrolled 78 patients with advanced solid tumors—over a quarter of whom were breast cancer patients. Among the 56 efficacy-evaluable patients, BG-C9074 demonstrated a confirmed overall response rate (ORR) of 16.1% and an unconfirmed ORR of 25%, with a disease control rate of 73.2%. These early signs of antitumor activity were achieved without patient selection based on B7-H4 expression, underscoring the therapy’s broad potential applicability.
Crucially, the drug’s safety profile was manageable, with dose-limiting toxicities limited to fatigue, febrile neutropenia, and platelet count decreases. No treatment-related deaths or discontinuations were reported. These results suggest that BG-C9074 may represent a viable new treatment option for heavily pretreated patients who have few remaining alternatives. The trial (NCT06233942) remains ongoing, and BeOne is expected to advance the compound into expansion cohorts and potentially pivotal studies.
CHECK THIS OUT: Gilead Sciences (GILD) is a Top Long-Term Biotech Investment for 2025 and CEL-SCI Corporation: Leading the Future of Cancer Immunotherapy with Multikine®.
BG-68501: A Potent CDK2 Inhibitor Designed to Overcome CDK4/6 Resistance
BeOne also presented Phase 1a data on BG-68501, a CDK2 inhibitor aimed specifically at hormone receptor-positive (HR+)/HER2-negative breast cancer—a subtype that comprises roughly two-thirds of all breast cancer cases worldwide. CDK2 activity and cyclin E1 overexpression are key resistance mechanisms that limit the durability of standard CDK4/6 inhibitors. BG-68501 is designed to directly counter these mechanisms.
In the ASCO study, 57 patients with advanced solid tumors—19 of whom had HR+/HER2- breast cancer—received the drug as monotherapy or in combination with fulvestrant. Although the unconfirmed ORR was modest at 5.4%, two patients achieved partial responses and another 15 achieved stable disease. More importantly, the disease control rate was nearly 46%, and no dose-limiting toxicities were observed. These findings support further development of BG-68501 as a potential next-line therapy for patients who have progressed on CDK4/6 inhibitors. The trial (NCT06257264) will continue to escalate and refine dosing regimens.
A Deep and Differentiated Breast Cancer Pipeline
The ASCO 2025 data add meaningful validation to BeOne’s broader breast cancer pipeline, which now includes three clinical-stage programs: BG-C9074 (ADC), BG-68501 (CDK2i), and BGB-43395 (CDK4i). In addition, BeOne plans to initiate clinical trials soon for BGB-21447, a next-generation BCL2 inhibitor, with applicability in breast and other solid tumors. The company is also developing multispecific antibodies and targeted protein degraders, reinforcing its commitment to bringing differentiated, mechanism-based therapies to patients with limited treatment options.
As breast cancer remains the most diagnosed cancer in women globally—with over 2.3 million new cases and 666,000 deaths reported annually—BeOne’s investment in novel modalities offers substantial medical and commercial opportunity. The company’s approach is not only to improve survival outcomes, but also to improve quality of life through intelligent, targeted therapy design and thoughtful patient experience support.
Financial Strength, Global Scale, and Upcoming Catalysts
BeOne’s commercial success with Brukinsa and its expansion into solid tumors have propelled the company into profitability. In Q1 2025, BeOne reported $1.1 billion in revenue and its first-ever quarterly profit with $1.22 EPS, confirming the scalability of its commercial and research platforms. The company’s stock has surged nearly 40% year-to-date, supported by strong technical scores and bullish analyst sentiment. With a consensus price target of $333, analysts see continued upside as clinical programs mature and new indications for Brukinsa, BG-C9074, and BG-68501 progress toward registrational trials.
Looking ahead, BeOne is preparing for a major Investor R&D Day on June 26, 2025, where it will highlight its global innovation platforms, next-gen R&D engine, and key value drivers across its hematology and solid tumor franchises. This event is likely to serve as a catalyst for further investor enthusiasm as BeOne deepens its narrative as a top-tier oncology innovator.
Conclusion: BeOne Medicines Is Poised to Lead the Future of Global Cancer Therapy
BeOne Medicines has rapidly evolved from an ambitious biotech into a global leader in oncology innovation, with a proven commercial engine, a strong clinical pipeline, and a clearly defined mission. The company’s latest clinical results at ASCO 2025 confirm its ability to deliver next-generation treatments in complex, high-need cancers like HR+/HER2- breast cancer. With a global infrastructure, cutting-edge science, and a deep bench of therapeutic candidates, BeOne is positioned to become not just a successful biotech—but a transformative force in how cancer is treated around the world.
For long-term investors seeking exposure to a high-growth oncology company with blockbuster potential and platform breadth, BeOne Medicines (NASDAQ: ONC) represents one of the most compelling opportunities in the biotech sector today.
READ ALSO: Incyte (INCY) is the Next Big Biotech Winner and Bluebird Bio (BLUE) Posts 108% Revenue Growth in Q1 2025 Amid Acquisition Buzz.
